- Home
- QSI vs KROS Comparison
QSI vs KROS Comparison
Compare QSI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- KROS
- Stock Information
- Founded
- QSI 2013
- KROS 2015
- Country
- QSI United States
- KROS United States
- Employees
- QSI N/A
- KROS N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- QSI Health Care
- KROS Health Care
- Exchange
- QSI Nasdaq
- KROS Nasdaq
- Market Cap
- QSI 226.8M
- KROS 565.0M
- IPO Year
- QSI N/A
- KROS 2020
- Fundamental
- Price
- QSI $1.26
- KROS $15.62
- Analyst Decision
- QSI Strong Buy
- KROS Buy
- Analyst Count
- QSI 3
- KROS 14
- Target Price
- QSI $2.38
- KROS $20.56
- AVG Volume (30 Days)
- QSI 5.6M
- KROS 412.4K
- Earning Date
- QSI 11-11-2025
- KROS 11-05-2025
- Dividend Yield
- QSI N/A
- KROS N/A
- EPS Growth
- QSI N/A
- KROS N/A
- EPS
- QSI N/A
- KROS 0.47
- Revenue
- QSI $3,412,000.00
- KROS $232,844,000.00
- Revenue This Year
- QSI N/A
- KROS $5,998.31
- Revenue Next Year
- QSI $219.33
- KROS N/A
- P/E Ratio
- QSI N/A
- KROS $33.74
- Revenue Growth
- QSI 100.47
- KROS 85820.30
- 52 Week Low
- QSI $0.61
- KROS $9.12
- 52 Week High
- QSI $5.77
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- QSI 53.14
- KROS 57.13
- Support Level
- QSI $0.95
- KROS $15.34
- Resistance Level
- QSI $1.16
- KROS $15.85
- Average True Range (ATR)
- QSI 0.08
- KROS 0.45
- MACD
- QSI 0.04
- KROS -0.02
- Stochastic Oscillator
- QSI 74.19
- KROS 57.08
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.